Results 181 to 190 of about 105,541 (302)

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Pathophysiological and therapeutic implications of C-type natriuretic peptide/cyclic GMP signaling in pulmonary fibrosis. [PDF]

JCI Insight
Weyer R, Völker K, Potapenko T, Krebes L, Abeßer M, Friedrich AL, Lessmann E, Khadim A, Ruppert C, El Agha E, Sheta D, Beilhack A, Santi DV, Schneider EL, Kuhn M, Dabral S.   +15 more
europepmc   +1 more source

Differential segment‐specific signalling pathways for guanylate cyclase C‐activated anion secretion in murine ileocolon

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Guanylate cyclase‐C (GC‐C) is the receptor for endogenous (uro)guanylin peptides, bacterial toxins and pharmacological analogues. Receptor activation leads to intestinal fluid loss, but also activates an antiproliferative pathway and is a promising target in colorectal cancer therapy.
Renjie Xiu, Johannes Reiner, Franz Hofmann, Azam Salari, Ursula Seidler   +4 more
wiley   +1 more source

The Anti-Apoptotic Effect of C-Type Natriuretic Peptide and the Regulation of NPPC in Porcine Ovarian Granulosa Cells. [PDF]

Int J Mol Sci
Liu X, Lu J, Zeng J, An L, Tian J, Xi G.
europepmc   +1 more source

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP. [PDF]

Br J Clin Pharmacol, 2022
Breinholt VM, Mygind PH, Christoffersen ED, Zhang Y, Ota S, Will Charlton R, Viuff D.   +6 more
europepmc   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

C-type natriuretic peptide mitigates apoptosis in ovarian granulosa cells through the cGMP pathway independent of PKG signaling. [PDF]

J Ovarian Res
Wei Y, Deng H, Liu Q, Wu Y, An L, Tian J, Xi G.   +6 more
europepmc   +1 more source

C-type natriuretic peptide facilitates autonomic Ca²⁺ entry in growth plate chondrocytes for stimulating bone growth. [PDF]

Elife, 2022
Miyazaki Y, Ichimura A, Kitayama R, Okamoto N, Yasue T, Liu F, Kawabe T, Nagatomo H, Ueda Y, Yamauchi I, Hakata T, Nakao K, Kakizawa S, Nishi M, Mori Y, Akiyama H, Nakao K, Takeshima H.   +17 more
europepmc   +1 more source

Circulating Musclin is associated with skeletal muscle function and subclinical cardiac dysfunction in patients with cancer

British Journal of Pharmacology, EarlyView.
Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer, Daniel Finke, Sebastian Romann, Norbert Frey, Joerg Heineke, Lorenz H. Lehmann   +5 more
wiley   +1 more source

Hypertrichosis associated with the use of C-type natriuretic peptide analogue: a case report. [PDF]

J Med Case Rep
Clinton JL, Magalhaes TSPC, Bordallo AP, Collett-Solberg PF.   +3 more
europepmc   +1 more source